Pennant Investors »

Zentalis Pharmaceuticals shares owned by Pennant Investors

Quarter-by-quarter ownership of Zentalis Pharmaceuticals (ZNTL) shares owned by Pennant Investors from 13F filings

Historical chart of Pennant Investors investment in Zentalis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Zentalis Pharmaceuticals held by Pennant Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zentalis Pharmaceuticals by Pennant Investors

Quarter filed Position value Share count Share price at filing
2024-03-31 $511k 32k 15.76

More positions owned by Pennant Investors

Amazon (AMZN)
TransDigm Group Incorporated (TDG)
Antero Res Call Option (AR)
Microsoft Corporation (MSFT)
Micron Technology (MU)
Echostar Corp Cl A (SATS)
Alphabet Cap Stk Cl A (GOOGL)
Apple Put Option (AAPL)
Colfax Corp (ENOV)
ODP Corp. (ODP)
Perimeter Solutions Sa Common Stock (PRM)
Fibrogen (FGEN)
Arcutis Biotherapeutics (ARQT)
Altimmune Com New (ALT)
Fate Therapeutics (FATE)

View all positions for Pennant Investors

Top funds holding Zentalis Pharmaceuticals

Eventide Asset Management
FMR
BlackRock
Vanguard Group
Citadel Advisors
T. Rowe Price Associates
T. Rowe Price Investment Management
Federated Investors
Decheng Capital
MPM Oncology Impact Management
Woodline Partners
Geode Capital Management
Verition Fund Management
Morgan Stanley
PRIMECAP Management Company

View all funds holding Zentalis Pharmaceuticals